Regeneus Ltd (ASX:RGS)


right-arrow Created with Sketch. 0.001 (1.41%)
MCAP $22.06M
Last trade 15.28pm 03/12/2021 20mins delayed

Latest Announcements

18/11/2021RGSRegeneus Ltd
18/11/2021RGSRegeneus Ltd
17/11/2021RGSRegeneus Ltd
05/11/2021RGSRegeneus Ltd
05/11/2021RGSRegeneus Ltd
29/10/2021 Price SensitivePSRGSRegeneus Ltd
28/10/2021RGSRegeneus Ltd
26/10/2021RGSRegeneus Ltd

Company Overview

Regeneus Ltd is an Australia-based, clinical-stage regenerative medicine company. The Company uses stem cell technologies to develop cell-based therapies. Its therapeutic areas include knee osteoarthritis, neuropathic pain and skin inflammation. The Company’s platform technologies consist of Progenza and Sygenus. The Progenza is a cellular therapy targeting pain and inflammation, which uses the secretome to improve Mesenchymal Signalling Cells (MSCs).The Progenza repairs local damaged tissue, such as cartilage tissue commonly found in joints like the knees and elbows. The Sygenus is a cell-free topical serum and gel treatment for pain and inflammation derived from Adipose MSCs. The Sygenus consists of selective bioactive molecules from the secretome. It reduces pain and inflammation, while accelerating tissue healing and repair.

RGS in the news

Clinical-stage regenerative medicine company Regeneus (RGS) has secured up to $4.5 million…
Regeneus (RGS) has partnered with Australia’s Department of Defence (DoD) to develop…
Clinical-stage regenerative medicine company Regeneus (RGS) has been given a notice of intention…
Clinical-stage regenerative medicine company Regeneus (RGS) has appointed Karolis Rosickas as CEO…

Search Previous Announcements